| Mucolytic Effectiveness of Tacholiquine ® in Chronic Bronchitis (NCT02515799) | bene-Arzneimittel GmbH | 2014-08-01 |
| European Home Mechanical Ventilation Registry (NCT02315339) | ResMed | 2014-08-01 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients (NCT02130635) | GlaxoSmithKline | 2014-07-31 |
| Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component (NCT02164539) | GlaxoSmithKline | 2014-07-01 |
| Evaluating the Effect of Oxygentherapy on Concentration at Chronic Lung Patients (NCT02125916) | University of Aarhus | 2014-07-01 |
| A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (NCT02164513) | GlaxoSmithKline | 2014-06-30 |
| Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy (NCT02173769) | Boehringer Ingelheim | 2014-06-01 |
| Feasibility of Inspiratory Muscle Training in People With COPD Who Decline Pulmonary Rehabilitation (NCT01956565) | Sheffield Teaching Hospitals NHS Foundation Trust | 2014-06-01 |
| Impact of "Telecoaching Program" on Physical Activity in Patients With COPD (NCT02158065) | KU Leuven | 2014-05-01 |
| Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers (NCT02148445) | University of Kansas Medical Center | 2014-05-01 |
| Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD) (NCT02105961) | GlaxoSmithKline | 2014-04-24 |
| Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients (NCT02105948) | GlaxoSmithKline | 2014-04-15 |
| Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (NCT02105974) | GlaxoSmithKline | 2014-04-07 |
| Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients. (NCT01837927) | Novartis Pharmaceuticals | 2014-04-01 |
| Downhill Walking Training in COPD (NCT02113748) | KU Leuven | 2014-04-01 |
| Nutritional Supplementation in Adults With Chronic Respiratory Disease (NCT02102009) | Laboratorios Ordesa | 2014-04-01 |
| Efficacy and Physiology of Nasal High Flow Therapy (NCT02083120) | Institut für Pneumologie Hagen Ambrock eV | 2014-04-01 |
| Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events (NCT02096731) | Boehringer Ingelheim | 2014-03-01 |
| To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways (NCT02085161) | Boehringer Ingelheim | 2014-03-01 |
| Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination (NCT02064504) | GlaxoSmithKline | 2014-02-19 |
| Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations (NCT02130193) | GlaxoSmithKline | 2014-02-13 |
| Teaching Inhaler Use With the INCA Device in a Community Pharmacy Setting (NCT02203266) | Beaumont Hospital | 2014-02-01 |
| Evaluation of Long-Acting Muscarinic Antagonists in COPD (NCT02039050) | University of Dundee | 2014-02-01 |
| A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects (NCT02006537) | GlaxoSmithKline | 2014-01-31 |
| Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD). (NCT01957150) | GlaxoSmithKline | 2014-01-28 |
| Post-hospitalisation Nutritional Support and Gait Speed in COPD (NCT02261350) | Royal Brompton & Harefield NHS Foundation Trust | 2014-01-01 |
| Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers (NCT02030535) | Boehringer Ingelheim | 2014-01-01 |
| A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD) (NCT01978145) | GlaxoSmithKline | 2013-11-14 |
| The Spiration Valve System for the Treatment of Severe Emphysema (NCT01989182) | Olympus Corporation of the Americas | 2013-11-08 |
| Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2) (NCT02006732) | Boehringer Ingelheim | 2013-11-01 |
| A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (NCT01966549) | Janssen Research & Development, LLC | 2013-11-01 |
| Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1) (NCT01964352) | Boehringer Ingelheim | 2013-11-01 |
| Ventilator Adapters for Combivent Respimat (NCT01969539) | Boehringer Ingelheim | 2013-10-14 |
| Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (NCT01957163) | GlaxoSmithKline | 2013-10-01 |
| Ipratropium Bromide in Peri-Operative COPD (NCT01943552) | Boehringer Ingelheim | 2013-10-01 |
| Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients (NCT01969721) | Boehringer Ingelheim | 2013-10-01 |
| Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2 (NCT02119286) | GlaxoSmithKline | 2013-10-01 |
| Severe Chronic Obstructive Pulmonary Disease Inhalation Profiles Comparison (NCT02076269) | GlaxoSmithKline | 2013-09-01 |
| BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis (NCT01958008) | Boehringer Ingelheim | 2013-09-01 |
| Handling Inhalers - Technique Error Comparison (HI-TEC) (NCT01794390) | Research in Real-Life Ltd | 2013-09-01 |
| Improving Communication About Serious Illness (NCT01933789) | University of Washington | 2013-09-01 |
| Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses (NCT01894386) | GlaxoSmithKline | 2013-07-15 |
| A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (NCT01879410) | GlaxoSmithKline | 2013-06-13 |
| Telehealth Program in Chronic Patients (NCT02269618) | Fondazione Salvatore Maugeri | 2013-06-01 |
| Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study. (NCT01899638) | GlaxoSmithKline | 2013-05-20 |
| DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD) (NCT01868009) | GlaxoSmithKline | 2013-05-01 |
| A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (NCT01822899) | GlaxoSmithKline | 2013-04-04 |
| Minimal Important Difference for the Glittre-ADL Test and London Chest Activity of Daily Living Scale (NCT03251781) | University of the State of Santa Catarina | 2013-04-01 |
| Telemedicine for Patients Suffering From COPD (Danish Telecare North Trial) (NCT01984840) | Aalborg University | 2013-04-01 |
| Pulmonary Rehabilitation in Functional Outcomes and Its Relationship With Morbidity and Mortality in Patients With COPD (NCT03692793) | University of the State of Santa Catarina | 2013-04-01 |
| Impact of Early Respiratory Rehabilitation in the Exacerbations of Re-admitted COPD Patients (NCT02190461) | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 2013-04-01 |
| A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (NCT01817764) | GlaxoSmithKline | 2013-03-01 |
| Preference Tiotropium Respimat Study in COPD (NCT01810692) | Boehringer Ingelheim | 2013-03-01 |
| Development and Validation of a Self-administered QUestionnaire to Identify Levers of Adhesion Behavior to Patient's Medication in Order to Adapt the Educational Monitoring. (NCT02865525) | University Hospital, Grenoble | 2013-03-01 |
| Abdominal Functional Electrical Stimulation to Reduce Hyperinflation in Chronic Obstructive Pulmonary Disease Patients (NCT02035228) | Liberate Medical | 2013-03-01 |
| A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (NCT02014480) | GlaxoSmithKline | 2013-02-01 |
| A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects (NCT01751113) | GlaxoSmithKline | 2013-02-01 |
| Impact of Feedback on Physical Activity and Health-related Outcomes During Pulmonary Rehabilitation in COPD (NCT02725931) | Aveiro University | 2013-02-01 |
| The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD (NCT01777334) | GlaxoSmithKline | 2013-01-23 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers (NCT01762774) | GlaxoSmithKline | 2013-01-16 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects (NCT01762878) | GlaxoSmithKline | 2013-01-09 |
| Prevalence of Different Haptoglobin Phenotypes in Patients With COPD- Frequent Exacerbators Versus Non Exacerbators (NCT01745419) | Carmel Medical Center | 2013-01-01 |
| Summer-Winter Variability in the Level of Physical Activity in Daily Life in Brazilian and Belgian Patients With COPD (NCT01779960) | Universidade Estadual de Londrina | 2013-01-01 |
| Extracorporeal CO2 Removal in Hypercapnic Patients (NCT02564406) | University of Roma La Sapienza | 2013-01-01 |
| Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks. (NCT01772147) | GlaxoSmithKline | 2013-01-01 |
| Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks (NCT01772134) | GlaxoSmithKline | 2013-01-01 |
| A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects (NCT01691547) | GlaxoSmithKline | 2012-12-17 |
| Self-care Program in the Prevention of Admissions of Patients (NCT01726244) | Basque Health Service | 2012-12-01 |
| RELOVAIR® Lung Deflation Study (NCT01691885) | GlaxoSmithKline | 2012-11-01 |
| COPD MSA 3 Regions: Epidemiology and Risk Factors of COPD in Rural Environment (BM3R) (NCT03299907) | Centre Hospitalier Universitaire de Besancon | 2012-11-01 |
| A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (NCT01706328) | GlaxoSmithKline | 2012-10-15 |
| Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg (NCT01716520) | GlaxoSmithKline | 2012-10-01 |
| A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD. (NCT01703845) | Boehringer Ingelheim | 2012-10-01 |
| Co-administration of Olodaterol Respimat® and Tiotropium Handihaler® (NCT01694771) | Boehringer Ingelheim | 2012-09-01 |
| Co-administration of Olodaterol Respimat® and Tiotropium Handihaler® (NCT01696058) | Boehringer Ingelheim | 2012-09-01 |
| Research to Evaluate a Possible Relation Between Values Obtained After Processing CT Images, Lung Function Tests and the Experience of the Patient During an Exacerbation in COPD Patients. (NCT01684384) | FLUIDDA nv | 2012-09-01 |
| Understanding and Appraising the New Medicine Service in England (NCT01635361) | University of Nottingham | 2012-08-01 |
| Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2 (NCT01662986) | Boehringer Ingelheim | 2012-08-01 |
| Long-term Safety Study for GSK573719 in Japanese (NCT01702363) | GlaxoSmithKline | 2012-08-01 |
| A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium (NCT01691482) | GlaxoSmithKline | 2012-07-23 |
| Physical Activity Augmentation Using Pedometers During Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (NCT01719822) | Royal Brompton & Harefield NHS Foundation Trust | 2012-07-01 |
| A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD (NCT01636713) | GlaxoSmithKline | 2012-07-01 |
| WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects (NCT01763463) | GlaxoSmithKline | 2012-07-01 |
| Effects of Salmeterol on Autonomic Nervous System (NCT01536587) | GlaxoSmithKline | 2012-07-01 |
| Smoking Cessation Intervention in Respiratory Inpatients (NCT02922387) | General Hospital of Kavala | 2012-05-01 |
| ADOAIR250 Anti-inflammatory Effects in Japanese Subjects With Chronic Obstructive Pulmonary Disease (NCT01607398) | GlaxoSmithKline | 2012-05-01 |
| Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease (NCT01627327) | GlaxoSmithKline | 2012-04-01 |
| Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide (NCT01543919) | Pfizer | 2012-04-01 |
| Home Telehealth Follow-up After Hospital Discharge for Chronic Obstructive Pulmonary Disease (COPD) Patients (NCT01512992) | Catalan Agency for Health Information, Assessment and Quality | 2012-04-01 |
| Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD) (NCT01253473) | National Jewish Health | 2012-04-01 |
| A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers (NCT01577680) | GlaxoSmithKline | 2012-03-05 |
| Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease (NCT01559116) | Boehringer Ingelheim | 2012-03-01 |
| A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD (NCT01525615) | Boehringer Ingelheim | 2012-02-01 |
| Japan Long-term Safety for Tiotropium Plus Olodaterol (NCT01536262) | Boehringer Ingelheim | 2012-02-01 |
| Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients. (NCT01533935) | Boehringer Ingelheim | 2012-02-01 |
| Respiratory and Cardiovascular Effects in COPD (NCT02729220) | Dr Annelie F Behndig, MD PhD | 2012-01-01 |
| eRT Remote Health Monitoring (NCT01495780) | University of California, Los Angeles | 2012-01-01 |
| Randomized Clinical Trial of a Pharmaceutical Care Program in Chronic Patients Users of an Emergency Department (NCT02368548) | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 2012-01-01 |
| QTc Study GSK573719+GW642444 (NCT01521377) | GlaxoSmithKline | 2011-12-19 |
| Evaluation With CT Scan of Possible Changes in Airways After Treatment With Daxas® in Severe Chronic Obstructive Pulmonary Disease Patients (NCT01480661) | FLUIDDA nv | 2011-12-01 |